Patent Issues in the Development of Biosimilar Medicines
Biosimilar medicines are already a commercial reality in the European Union. The U.S. Healthcare Reform legislation – with its defined pathway for the regulatory approval of follow-on biologics – should open up the U.S. market in the future, but in the meantime, the next batch of biosimilars will face other difficulties in reaching the market, …
Click here to read full Press Release